FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3192246685> ?p ?o ?g. }

• W3192246685 abstract "Ovarian cancer is a leading cause of death among gynecological malignancies, and novel therapies are urgently needed. Here we report preliminary findings on the potential safety and efficacy of 6B11-OCIK, an adoptive cell therapy of autologous T cells induced by the humanized anti-idiotypic antibody 6B11 minibody plus dendritic cells and cytokines, against platinum-resistant recurrent or refractory ovarian cancer in three patients. We found that 6B11-OCIK treatment was safe and well tolerated after five cycles of intravenous infusion with an initial dose of 1-2×109 cells and a dose-climbing strategy. Hemoglobin, platelets, white cell count, creatinine or liver enzyme values, coagulation function, kidney and heart function were not significantly affected over the duration of therapy. Two of the three enrolled patients showed potentially drug-related grade 1 and 2 weakness, and no other adverse events were observed. Of the three enrolled patients, one had stable disease and two showed disease progression. The patient with favorable clinical efficacy had better immune response as measured by 6B11-OCIK proliferation capacity, activation ability of CD3+CD8+ tumor-specific cytotoxic T lymphocytes and CD3+CD56+ cytokine-induced killer cells, and tumor cell killing efficiency. Changes in circulating tumor cells after treatment were consistent with serum level CA125 in the patient with stable disease (both decreased), while differences were observed in the two patients with disease progression (increased CA125 in both and decreased CTC in the patient with better immune response), suggesting that variation of circulating tumor cells was more consistent with immune response and reflected efficacy directly. This preliminary study suggested that autologous 6B11-OCIK treatment was safe and had potential clinical efficacy against ovarian cancer. Patients with better immune response had more favorable efficacy. In addition to imaging, CA125 and immunophenotypes, CTC monitoring may represent a potential indicator of immunotherapy response." @default.
• W3192246685 created "2021-08-16" @default.
• W3192246685 creator A5003256933 @default.
• W3192246685 creator A5007759257 @default.
• W3192246685 creator A5018426593 @default.
• W3192246685 creator A5021506689 @default.
• W3192246685 creator A5034079610 @default.
• W3192246685 creator A5043542554 @default.
• W3192246685 creator A5047153226 @default.
• W3192246685 creator A5053835044 @default.
• W3192246685 creator A5054350423 @default.
• W3192246685 creator A5064842058 @default.
• W3192246685 creator A5065985958 @default.
• W3192246685 creator A5066738831 @default.
• W3192246685 creator A5079594267 @default.
• W3192246685 creator A5080214478 @default.
• W3192246685 creator A5080562594 @default.
• W3192246685 creator A5083955051 @default.
• W3192246685 creator A5091913838 @default.
• W3192246685 date "2021-08-02" @default.
• W3192246685 modified "2023-10-15" @default.
• W3192246685 title "Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer" @default.
• W3192246685 cites W2032174355 @default.
• W3192246685 cites W2033816200 @default.
• W3192246685 cites W2040859464 @default.
• W3192246685 cites W2078422533 @default.
• W3192246685 cites W2087376277 @default.
• W3192246685 cites W2088356680 @default.
• W3192246685 cites W2106767659 @default.
• W3192246685 cites W2125346526 @default.
• W3192246685 cites W2132020367 @default.
• W3192246685 cites W2135700359 @default.
• W3192246685 cites W2151509048 @default.
• W3192246685 cites W2167804513 @default.
• W3192246685 cites W2211065115 @default.
• W3192246685 cites W2274165065 @default.
• W3192246685 cites W2396404964 @default.
• W3192246685 cites W2396594210 @default.
• W3192246685 cites W2550385303 @default.
• W3192246685 cites W2579112568 @default.
• W3192246685 cites W2589824589 @default.
• W3192246685 cites W2592144107 @default.
• W3192246685 cites W2592948192 @default.
• W3192246685 cites W2625028514 @default.
• W3192246685 cites W2740854916 @default.
• W3192246685 cites W2761920752 @default.
• W3192246685 cites W2770312776 @default.
• W3192246685 cites W2771290640 @default.
• W3192246685 cites W2773771998 @default.
• W3192246685 cites W2775990182 @default.
• W3192246685 cites W2782217647 @default.
• W3192246685 cites W2795929251 @default.
• W3192246685 cites W2811158315 @default.
• W3192246685 cites W2898996259 @default.
• W3192246685 cites W2900741477 @default.
• W3192246685 cites W2901042358 @default.
• W3192246685 cites W2901419588 @default.
• W3192246685 cites W2911188335 @default.
• W3192246685 cites W2915478882 @default.
• W3192246685 cites W2917185006 @default.
• W3192246685 cites W2949193276 @default.
• W3192246685 cites W2970713591 @default.
• W3192246685 cites W2994588445 @default.
• W3192246685 doi "https://doi.org/10.3389/fimmu.2021.707468" @default.
• W3192246685 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8366315" @default.
• W3192246685 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34408750" @default.
• W3192246685 hasPublicationYear "2021" @default.
• W3192246685 type Work @default.
• W3192246685 sameAs 3192246685 @default.
• W3192246685 citedByCount "3" @default.
• W3192246685 countsByYear W31922466852022 @default.
• W3192246685 countsByYear W31922466852023 @default.
• W3192246685 crossrefType "journal-article" @default.
• W3192246685 hasAuthorship W3192246685A5003256933 @default.
• W3192246685 hasAuthorship W3192246685A5007759257 @default.
• W3192246685 hasAuthorship W3192246685A5018426593 @default.
• W3192246685 hasAuthorship W3192246685A5021506689 @default.
• W3192246685 hasAuthorship W3192246685A5034079610 @default.
• W3192246685 hasAuthorship W3192246685A5043542554 @default.
• W3192246685 hasAuthorship W3192246685A5047153226 @default.
• W3192246685 hasAuthorship W3192246685A5053835044 @default.
• W3192246685 hasAuthorship W3192246685A5054350423 @default.
• W3192246685 hasAuthorship W3192246685A5064842058 @default.
• W3192246685 hasAuthorship W3192246685A5065985958 @default.
• W3192246685 hasAuthorship W3192246685A5066738831 @default.
• W3192246685 hasAuthorship W3192246685A5079594267 @default.
• W3192246685 hasAuthorship W3192246685A5080214478 @default.
• W3192246685 hasAuthorship W3192246685A5080562594 @default.
• W3192246685 hasAuthorship W3192246685A5083955051 @default.
• W3192246685 hasAuthorship W3192246685A5091913838 @default.
• W3192246685 hasBestOaLocation W31922466851 @default.
• W3192246685 hasConcept C121608353 @default.
• W3192246685 hasConcept C126322002 @default.
• W3192246685 hasConcept C143998085 @default.
• W3192246685 hasConcept C154317977 @default.
• W3192246685 hasConcept C167672396 @default.
• W3192246685 hasConcept C185592680 @default.
• W3192246685 hasConcept C202751555 @default.
• W3192246685 hasConcept C203014093 @default.
• W3192246685 hasConcept C2780427987 @default.

• next